NVO

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Novo Nordisk said on Monday it had halted two additional trials of ​its experimental cardiovascular drug ziltivekimab, further denting ‌the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.

The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.

Novo Nordisk has launched its Wegovy pill in Germany, a spokesperson for the Danish drugmaker said on Tuesday, with investors keenly focused on the ​oral weight-loss treatment in light of intensifying competition with U.S. rival Eli ‌Lilly.

NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.

Novo Nordisk shares fell on Thursday after Deutsche Bank downgraded the Danish drugmaker to Sell from Hold and lowered its price target, citing concerns over the company's growth prospects. The company's US shares declined about 2% in trading, with Deutsche Bank cutting its target to 265 Danish kroner from 290 kroner.

Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growth and navigate an impending patent cliff.

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.

Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their target price as midterm growth concerns and pipeline issues mount. The shares dropped 2.52% to DKK 297.25 as the broker adjusted its rating to 'sell', moving down from a previous 'hold' view following the drugmaker's mixed second-quarter update.